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Purpose: To evaluate the pharmacokinetic properties of besifloxacin, gatifloxacin, and 
  moxifloxacin in the conjunctival tissue of healthy volunteers after topical application.
Methods: One-hundred eight (108) subjects were randomly assigned to receive one drop of 
besifloxacin (0.6% suspension), gatifloxacin (0.3% solution), or moxifloxacin (0.5% solution) 
ophthalmic formulations in one eye prior to conjunctival biopsy. Conjunctival samples were 
taken from subjects at either 15 minutes, 30 minutes, 2 hours, 6 hours, 12 hours, or 24 hours 
after dosing.
Results: All three fluoroquinolones reached a peak mean concentration 15 minutes after 
  dosing. The mean concentrations of besifloxacin, gatifloxacin, and moxifloxacin at 15 minutes 
were 2.30 ± 1.42 µg/g, 4.03 ± 3.84 µg/g, and 10.7 ± 5.89 µg/g, respectively. Concentrations 
decreased with each subsequent time point. At 24 hours after dosing, concentrations of besi-
floxacin were measurable in 4 of 6 subjects, compared with 3 of 6 subjects for gatifloxacin and 
2 of 6 subjects for moxifloxacin. Besifloxacin had the greatest mean residence time (4.7 hours) 
in the conjunctival tissue. With regard to methicillin-resistant strains of Staphylococcus aureus 
and Staphylococcus epidermidis, besifloxacin had the greatest area-under-the-curve (AUC) to 
MIC90 ratio. Nine percent (9%) of study subjects (N = 7) experienced a transient reduction in 
visual acuity.
Conclusion:  All three fluoroquinolones were well tolerated and reached levels in the conjunctiva 
above the MIC90s of methicillin-sensitive S. aureus and S. epidermidis for at least 2 hours.
Keywords:  besifloxacin, fluoroquinolone, conjunctivitis, pharmacokinetics, minimum inhibitory 
concentration
Introduction
Bacterial conjunctivitis is normally an acute, self-limiting infection. Recent phase 
3 clinical trials have demonstrated that the most common conjunctivitis pathogens 
are the Gram-positive species Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus pneumonia and the Gram-negative species Haemophilus influenzae.1,2 
In clinical practice, suspected cases of bacterial conjunctivitis are generally treated 
with broad-spectrum, topical antibiotics to increase the speed of recovery from signs 
and symptoms associated with the infection. Untreated cases of acute bacterial con-
junctivitis may become chronic or may develop into a more serious condition such 
as bacterial keratitis.3 A recent meta-analysis compared antibiotic treatment versus 
placebo for acute conjunctivitis in five clinical trials (N = 1034) and found that groups 
receiving an antibiotic experienced significantly less time to clinical resolution and 
microbial eradication.4 Faster resolution of infection translates to fewer days out Clinical Ophthalmology 2010:4 332
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concentration and antimicrobial activity, or pharmacodynam-
ics (PD), can then be quantified using the ratio of Cmax to 
MIC90, which represents the ratio of the peak concentration to 
the minimum concentration needed to inhibit 90% of isolates 
(MIC90) of a particular pathogen. In addition, fluoroquinolone 
antimicrobial activity can be quantified using the ratio of the 
AUC0–24 h to the MIC90 (AUC0–24 h:MIC90). These PK/PD ratios 
(Cmax:MIC90 and AUC24:MIC90) have been used to predict 
clinical outcome and microbiological success as well as to 
predict a decreased potential for development of bacterial 
resistance for FQs.9,10 For FQs, which are concentration-
dependent antibiotics, the AUC0–24 h:MIC90 is considered a 
more clinically relevant ratio.11–14
The purpose of this study was to evaluate the PK profiles 
of 3 FQs in the conjunctiva of healthy adults. Drug concen-
trations in conjunctiva were compared at collection intervals 
ranging from 15 minutes to 24 hours after a single dose. 
A conjunctival biopsy procedure was employed to collect 
tissue samples from study participants. This methodology was 
based on previous conjunctival biopsy studies that analyzed 
concentrations of ophthalmic antibiotics, including gatifloxa-
cin and moxifloxacin.15,16 These studies examined the drug 
concentrations at time-points ranging from 20 minutes to 
24 hours. To date, no studies have been conducted to deter-
mine the PK profile of besifloxacin in human conjunctiva. 
In a tear concentration PK study, topical administration of a 
single dose of besifloxacin 0.6% resulted in a maximum tear 
concentration in humans of 610 ± 540 µg/g, at 15 minutes 
post-instillation, with an average concentration of 1.6 µg/g 
or higher sustained for at least 24 hours.17
Methods
This single-dose, randomized, double-masked, active-
controlled study was conducted at one center in Andover, 
of work or school and decreases the chance of spreading 
infection to others.
Several recent studies have implicated drug-resistant 
pathogens in bacterial conjunctivitis.5 Other studies have 
demonstrated an increasing frequency of resistant organisms 
observed in ocular infections.6 In light of this, there is a grow-
ing need for an ophthalmic antibiotic with improved efficacy 
against organisms such as methicillin-resistant S. aureus 
(MRSA). Even among methicillin-sensitive S. aureus ocular 
isolates, there is a resistance rate of 20% to ciprofloxacin and 
of 46% to azithromycin.6 Methicillin resistance has also been 
found among S. epidermidis ocular isolates.7
Currently, multiple broad-spectrum antibiotics are 
approved for the treatment of conjunctivitis. The drug 
approved most recently for the treatment of bacterial 
conjunctivitis is besifloxacin (Besivance®; Bausch and 
Lomb, Inc., Rochester, New York, USA), a novel, synthetic 
chloro-fluoroquinolone (FQ) developed exclusively for oph-
thalmic use. Like other fluoroquinolones (FQs), besifloxacin 
targets DNA gyrase and topoisomerase IV, bacterial enzymes 
required for DNA replication. However, besifloxacin offers 
more balanced activity against these enzymes than do other 
FQs.8 In addition, besifloxacin has been found to have greater 
in vitro activity than gatifloxacin and moxifloxacin against 
several drug-resistant organisms, including MRSA and 
methicillin-resistant S. epidermidis (MRSE) (Table 1).7
A key factor in the clinical efficacy of an antibiotic is 
the concentration it is able to achieve in infected tissues. An 
antibiotic’s concentration in tissue over time can be deter-
mined by pharmacokinetic (PK) studies. Parameters derived 
from PK studies include an antibiotic’s peak concentration 
(Cmax) as well as its total area-under-the-concentration-ver-
sus-time curve during a 24-hour interval (AUC0–24 h). For 
fluoroquinolone antibiotics, the relationship between tissue 
Table 1 Minimum inhibitory concentrations (MIC90) for besifloxacin, moxifloxacin, and gatifloxacin against selected Staphylococcus isolates
   Number of isolates  Besifloxacin  
MIC90 (µg/mL)
Moxifloxacin  
MIC90 (µg/mL)
Gatifloxacin 
MIC90 (µg/mL)
S. aureus
  MSSA-CSa 144 0.06 0.12 0.25
  MRSA-CRb 81 4 32 64
S. epidermidis
  MSSE-CSc 50 0.06 0.12 0.25
  MRSE-CRd 29 4 64 128
aMIC90 values were obtained from susceptibility testing of 144 methicillin-sensitive, ciprofloxacin-sensitive S. aureus isolates.7
bMIC90 values were obtained from susceptibility testing of 81 methicillin-resistant, ciprofloxacin-resistant S. aureus isolates.24
cMIC90 values were obtained from susceptibility testing of 50 methicillin-sensitive, ciprofloxacin-sensitive S. epidermidis isolates.7
dMIC90 values were obtained from susceptibility testing of 29 methicillin-resistant, ciprofloxacin-resistant S. epidermidis isolates.24
Abbreviations: MIC90, minimum inhibitory concentration to inhibit 90% of isolates; MSSA-CS, methicillin- and ciprofloxacin-sensitive S. aureus; MRSA-CR, methicillin- and 
ciprofloxacin-resistant S. aureus; MSSE-CS, methicillin- and ciprofloxacin-sensitive S. epidermidis; MRSE-CR, methicillin- and ciprofloxacin-resistant S. epidermidis.Clinical Ophthalmology 2010:4 333
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Mass., between March and April of 2009. The study was 
conducted in accordance with Good Clinical Practices, the 
Declaration of Helsinki, and was approved by IntegReview 
Institutional Review Board, Inc. (Austin, Texas, USA). Prior 
to enrollment in the study, all subjects gave written informed 
consent and provided a Health Insurance Portability and 
Accountability Act (HIPAA) authorization form.
Study criteria
Subjects were healthy volunteers of at least 18 years of age 
and had no ocular abnormalities that would affect the param-
eters of the study. Best-corrected visual acuity (BCVA) had 
to be 0.60 logMAR or better in each eye as measured on the 
Early Treatment of Diabetic Retinopathy Study (ETDRS) 
chart. Subjects were excluded if they had undergone ocular 
surgery less than 3 months prior to the start of the study. 
Women of childbearing potential were excluded if they 
were pregnant, planning a pregnancy, or breastfeeding. 
Urine pregnancy tests were performed at Visit 1, Visit 2 or 
2a, and at Visit 4. Any subjects with known hypersensitivity 
or allergy to any of the study medications were excluded. 
In addition, subjects with a history of a bleeding disorder, 
bleeding complications, or fainting during surgical proce-
dures were excluded.
The use of certain medications was disallowed for the 
duration of the study. These included aspirin (daily dose 
greater than 81 mg), other anticoagulants, and anti-infective 
medications. The washout period for these medications was 
2 weeks prior to Visit 1. In addition, any topical ophthalmic 
preparations were disallowed for 1 week prior to Visit 1 and 
throughout the study. Contact lens wearers were required to 
discontinue use for at least 3 days prior to the conjunctival 
biopsy procedure and for the duration of the study.
At all study visits, subjects were queried for adverse 
events (AEs).
Enrollment
Subjects were screened for enrollment at Visit 1 only 
after providing written informed consent. Subjects’ demo-
graphic data, medical history, and medication history was 
then recorded. BCVA was measured using the ETDRS 
chart. An undilated biomicroscopy slit-lamp exam was 
performed to examine both eyes for tissue abnormalities 
or other ocular disease. The eye with worse visual acuity 
(VA) was selected for biopsy. If a subject had equivalent 
VA in both eyes, the biopsy site was selected as the non-
dominant eye as determined by the subject. Eligible subjects 
were randomized in a 1:1:1 ratio to receive one dose of 
besifloxacin, moxifloxacin, or gatifloxacin. Each subject 
was also randomized to one biopsy collection interval 
of 15 ± 1 minutes, 30 ± 1 minutes, 2 hours ± 5 minutes, 
6 hours ± 15 minutes, 12 hours ± 15 minutes, or 24 hours ± 15 
minutes after drug instillation. This randomization scheme 
created a total of 18 treatment cohorts (n = 6 per cohort), 
each assigned a unique combination of antibiotic and biopsy 
collection time. In order to maintain a balance in the treatment 
groups, subjects who were discontinued prior to biopsy were 
replaced by the next subject enrolled.
Treatment and biopsy
The 15-minute, 30-minute, 2-hour, and 6-hour groups 
received treatment and underwent conjunctival biopsy at a 
single visit (Visit 2, Day 0). The 12-hour and 24-hour groups 
received treatment at Visit 2a (Day 0) before returning for the 
biopsy procedure at Visit 2 (Day 1). Each subject received 
one dose of besifloxacin (Besivance®; Bausch and Lomb, 
Inc., Rochester, New York, USA), moxifloxacin (Vigamox®; 
Alcon Laboratories, Inc., Fort Worth, Texas, USA), or gati-
floxacin (Zymar®; Allergan, Inc., Irvine, California, USA) 
in the biopsy eye only. At Visits 2a and 2, subjects were 
asked to provide any updates to their medical and medica-
tion histories. BCVA was measured and a slit-lamp exam 
was performed prior to drug instillation. For subjects in the 
12- and 24-hour cohorts, BCVA and slit-lamp exams were 
performed a second time at Visit 2 prior to biopsy.
Prior to the biopsy procedure, the study eye was verbally 
confirmed. A 5% povidone-iodine (P-I) solution was instilled 
in the study eye after periocular skin was sterilized with 10% 
P-I. The investigator then removed two tissue samples from 
the nasal and temporal regions of the inferior palpebral con-
junctiva. Samples were weighed and immediately transferred 
to a freezer at –80°C. Samples were later repackaged on dry 
ice and shipped to Bausch and Lomb, Inc. (Rochester, New 
York, USA) for analysis.
After the biopsy procedure at Visit 2, subjects were given 
loteprednol etabonate 0.5% with tobramycin 0.3% (Zylet®; 
Bausch and Lomb, Rochester, New York, USA) to use 4 times 
a day for 5 days to prevent infection and inflammation at the 
biopsy site.
Subjects were required to return for follow-up at Visit 3 
(Day 1 ± 1) and Visit 4 (Day 6 ± 1). Medical and medication 
history updates were collected prior to BCVA measurement and 
slit-lamp exam. Per protocol, expected signs and symptoms of 
the biopsy procedure (eg, mild ocular pain, mild edema at or 
around the biopsy site, mild bleeding at the biopsy site) were 
not classified as adverse events for this study.Clinical Ophthalmology 2010:4 334
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Conjunctival concentration analyses
PK analyses were performed on the modified intent-to-treat 
(mITT) population (N = 108). Conjunctival biopsy samples 
were analyzed for concentrations of besifloxacin, moxifloxacin, 
and gatifloxacin using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) with a Sciex API 4000 triple quad-
rupole mass spectrometer (Applied Biosystems, Foster City, 
California, USA) with a TurboIonSpray® source. An XBridge™ 
C18 (2.1 × 50 mm, 3.5-µm particle size) column (Waters Cor-
poration, Milford, Massachusetts, USA) with a mobile phase 
of a 20/80 (v/v) mixture of acetonitrile/water + 0.2% formic 
acid was used. The lower limit of quantitation (LLOQ) for each 
analyte was 17.9 ng/g (ng of drug per gram of tissue).
Statistical analyses
PK calculations were performed using SAS version 9.1 
(SAS Institute, Inc., Cary, North Carolina, USA). Concentra-
tions that were below the limit of quantitation (BLQ) were 
assigned a value of 8.95 ng/g, which is equal to one-half the 
value of the LLOQ (17.9 ng/g). This rationale was employed 
because it is improbable that the drug concentrations were 
equal to zero in these samples, while the results of the analysis 
confirmed that the concentrations were less than 17.9 ng/g.
Results
The study included a total of 119 participants, including 
46 males and 73 females (Table 2). Subjects ranged from 
18 to 74 years of age, with a mean age of 42.6 years. Approxi-
mately 9% (11/119) of the study subjects were non-white. 
Demographic characteristics were similar between treatment 
groups. Brown was the most common iris color overall (in 
55/119, or 46.2% of subjects) and within each of the three 
treatment groups.
Out of the 119 subjects enrolled, a total of 108 underwent 
biopsy (Table 3; Figure 1). Eleven (11) subjects (9.2% of 
those enrolled) were discontinued from the study prior to 
biopsy: 3 because of adverse events, 2 after withdrawing 
consent, and the remaining 6 for various reasons. The mITT 
population consisted of 108 subjects and was used for the 
primary PK analysis. The safety population, which included 
all subjects that received at least one dose of medication, 
consisted of 109 subjects. In total, 36 subjects per treatment 
arm completed the study.
Biopsy
One hundred nine (109) subjects were dosed. Of those, 
108 underwent biopsy. One subject received a dose of 
Table 2 Demographics of intent-to-treat (ITT) population
  Besifloxacin 0.6% N = 38 Moxifloxacin 0.5% N = 38 Gatifloxacin 0.3% N = 43 Total N = 119
Age (years)
  Mean (SD) 42.5 (14.3) 40.5 (15.0) 44.6 (17.0) 42.6 (15.5)
  Range 20–66 18–68 18–74 18–74
Gender
  Male 17 (44.7%) 12 (34.2%) 16 (37.2%) 46 (38.7%)
  Female 21 (55.3%) 25 (65.8%) 27 (62.8%) 73 (61.3%)
Ethnicity
  Hispanic or Latino 3 (7.9%) 5 (13.2%) 2 (4.7%) 10 (8.4%)
  Not Hispanic or Latino 35 (92.1%) 33 (86.8%) 41 (95.3%) 109 (91.6%)
Race
  American Indian/Alaskan Native 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.8%)
  Asian 0 (0.0%) 1 (2.6%) 1 (2.3%) 2 (1.7%)
  Black/African-American 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.8%)
  White 35 (92.1%) 34 (89.5%) 39 (90.7%) 108 (90.8%)
  Other 1 (2.6%) 3 (7.9%) 3 (7.0%) 7 (5.9%)
Iris color
  Blue 10 (26.3%) 7 (18.4%) 10 (23.3%) 27 (22.7%)
  Brown 15 (39.5%) 19 (50.0%) 21 (28.8%) 55 (46.2%)
  Green 2 (5.3%) 4 (10.5%) 5 (11.6%) 11 (9.2%)
  Hazel 11 (28.9%) 8 (21.1%) 7 (16.3%) 26 (21.8%)
Notes: Subject-reported races designated as ‘Other’ include: Native Indian/Latino (1), Spanish (1), Polish (1), Mulatto (1), Hispanic (1), and Puerto Rican (2).
Abbreviation: SD, standard deviation.Clinical Ophthalmology 2010:4 335
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  besifloxacin but did not undergo biopsy because the 
  preparation work for the biopsy was unintentionally com-
pleted 1 hour prior to the scheduled time. As a result, the 
subject was discontinued prior to biopsy. All 108 biopsy 
specimens provided sufficient tissue mass for the drug 
level analysis. A nasal specimen was not collected for one 
subject in the moxifloxacin 15-minute cohort; however, 
that subject’s temporal section provided enough tissue for 
analysis. One biopsy in the 24-hour besifloxacin cohort 
was performed 12 minutes out-of-window, at 24 hours and 
27 minutes after drug instillation. However, this sample 
was still included in the tissue analysis because it was not 
substantially out-of-window.
Pharmacokinetic analyses
Mean and median conjunctival drug concentrations for the 
18 treatment cohorts at each collection time are provided in 
Table 4. The maximum mean concentration (Cmax) occurred 
at 15 minutes for all three compounds. The Cmax for moxi-
floxacin (10.7 µg/g) was more than double that of gatifloxacin 
(4.03 µg/g) and besifloxacin (2.30 µg/g). Whereas concen-
trations at 30 minutes for moxifloxacin and gatifloxacin 
were approximately half those of the respective 15 minute 
time-points, the mean concentration of besifloxacin remained 
stable between 15 minutes (2.30 ± 1.42 µg/g) and 30 minutes 
(2.29 ± 1.30 µg/g). For all three FQs, the mean concentrations 
declined with each successive time-point.
Randomized
(ITT)
N = 119
Completed
(mITT) N = 108
Per-
protocol
N = 106
Adverse event
N = 3
(1 besifloxacin,
2 gatifloxacin)
Protocol
violation
N = 2
(1 besifloxacin,
1 moxifloxacin)
Consent
withdrawn
N = 2
(2 gatifloxacin)
Administrative
reasons
N = 2
(2 gatifloxacin)
Other*
N = 2
(1 gatifloxacin)
Discontinued
N = 11
Figure 1 Disposition of enrolled subjects.
aIncludes 1 subject discontinued due to investigator’s decision and 1 subject discontinued due to pregnancy. In the latter case, the subject had a negative pregnancy test at 
Visit 1, but reported that she had a positive pregnancy test prior to Visit 2a. The subject was discontinued immediately before the scheduled Visit 2a and did not receive any 
test medications.
Abbreviations: ITT, intent-to-treat population; mITT, modified intent-to-treat population.
Table 3 Disposition of enrolled subjects
Besifloxacin 0.6% Moxifloxacin 0.5% Gatifloxacin 0.3% Total
Randomized (ITT) 38 (100%) 38 (100%) 43 (100%) 119 (100%)
Completed (mITT) 36 (94.7%) 36 (94.7%) 36 (83.7%) 108 (90.8%)
Safety population 38 (100%) 36 (94.7%) 37 (86.0%) 111 (93.3%)
Per-protocol population 35 (92.1%) 36 (94.7%) 35 (81.4%) 106 (89.1%)
Discontinued 2 (5.3%) 2 (5.3%) 7 (16.3%) 11 (9.2%)
  Adverse event 1 (2.6%) 0 (0.0%) 2 (4.7%) 3 (3.5%)
  Consent withdrawn 0 (0.0%) 0 (0.0%) 2 (4.7%) 2 (1.7%)
  Investigator’s decision 0 (0.0%) 1 (2.6%) 0 (0.0%) 1 (0.8%)
  Protocol violation 1 (2.6%) 1 (2.6%) 0 (0.0%) 2 (1.7%)
  Administrative reasons 0 (0.0%) 0 (0.0%) 2 (4.7%) 2 (1.7%)
  Pregnancya 0 (0.0%) 0 (0.0%) 1 (2.3%) 1 (0.8%)
aSubject had a negative pregnancy test at Visit 1, but reported a positive pregnancy test prior to Visit 2a. The subject was discontinued immediately and did not receive any 
test medications.
Abbreviations: ITT, intent-to-treat population; mITT, modified intent-to-treat population.Clinical Ophthalmology 2010:4 336
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In 9 out of the 108 biopsy specimens, the drug 
concentration was below the LLOQ. All of these BLQ 
samples were from the 24-hour collection time. These 
specimens were assigned a value of 8.95 ng/g, per 
the rationale articulated in the Methods section. The 
besifloxacin group had the greatest number of subjects 
with quantifiable amounts of drug in the tissue at 24 hours 
(4/6), compared with the gatifloxacin group (3/6 subjects) 
and the moxifloxacin group (2/6 subjects). At 24 hours 
post-instillation, the mean concentrations were 0.034 ± 
0.026 µg/g for besifloxacin, 0.025 ± 0.031 µg/g for moxi-
floxacin, and 0.019 ± 0.013 µg/g for gatifloxacin. Because 
of the relatively small sample size at the 24-hour collection 
and the prevalence of BLQ samples in this collection group, 
the apparent differences in concentrations at 24 hours should 
be interpreted with caution. To aid in this assessment, the 
results for each individual sample in the 24-hour collection 
group is presented in Figure 2.
A concentration-time curve was constructed using the 
mean concentration data for each FQ (Figure 3). The total 
area-under-the-curve from time of dosing to 24 hours 
post-instillation (AUC0–24 h) was then calculated for each 
drug (Table 5). The AUC0–24 h for moxifloxacin, 11.1 µg/g, 
was almost 2 times greater than the AUC0–24 h for besifloxacin 
(6.65 µg/g) and for gatifloxacin (6.10 µg/g). However, the 
same concentration-time curve reveals that besifloxacin had 
the longest mean residence time (MRT) in the conjunctiva, 
at 4.7 hours.
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Figure 2 Conjunctival fluoroquinolone concentrations (µg/g) in individual subjects at 24 hours (mITT population).
Abbreviations: mITT, modified intent-to-treat population (N = 108); BLQ, concentration below the limit of quantitation (17.9 ng/g).
Table 4 Mean and median fluoroquinolone concentrations in conjunctival tissue (mITT population)
Besifloxacin  
0.6% (µg/g)  
N = 36
Moxifloxacin  
0.5% (µg/g)  
N = 36
Gatifloxacin 
0.3% (µg/g)  
N = 36
15 minutes Mean (SD) 2.30 (1.42) 10.7 (5.89) 4.03 (3.84)
Median 1.65 9.23 3.04
30 minutes Mean (SD) 2.29 (1.30) 4.04 (4.16) 2.76 (0.737)
Median 1.75 2.80 2.61
2 hours Mean (SD) 0.418 (0.281) 0.845 (0.440) 0.448 (0.284)
Median 0.442 0.917 0.444
6 hours Mean (SD) 0.324 (0.355) 0.228 (0.162) 0.162 (0.205)
Median 0.161 0.184 0.0936
12 hours Mean (SD) 0.122 (0.196) 0.146 (0.123) 0.0586 (0.0675)
Median 0.0447 0.134 0.0311
24 hours Mean (SD) 0.0338 (0.0262) 0.0248 (0.0309) 0.0186 (0.0133)
Median 0.0309 0.00895 0.0127
Notes: Biopsies were performed at 15 ± 1 minute, 30 ± 1 minute, 2 hours ± 5 minutes, 6 hours ± 15 minutes, 12 hours ± 15 minutes, and 24 hours ± 15 minutes. Biopsy 
samples containing a concentration of drug below the lower limit of quantitation (LLOQ = 17.9 ng/g) were assigned a value equal to one-half the LLOQ (8.95 ng/g).
Abbreviations: mITT, modified intent-to-treat population (N = 108); SD, standard deviation.Clinical Ophthalmology 2010:4 337
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Safety outcomes
No serious AEs (SAEs) occurred in this study. There were 11 
treatment-related AEs that were mild or moderate in nature 
(Table 6). Overall, 9.2% of subjects in the safety population 
(10/109) experienced a treatment-related AE. There were 4 
AEs in the moxifloxacin group (11.1% of subjects), 4 AEs 
in the besifloxacin group (10.8% of subjects), and 2 AEs in 
the gatifloxacin group (5.6% of subjects). The most com-
monly reported adverse events were ocular pain (N = 5) and 
headache (N = 2).
Discussion
Although multiple topical ocular antibiotics are available, 
each has unique pharmacokinetic (PK) and pharmacody-
namic (PD) properties that influence its therapeutic value. 
The aim of the present study was to characterize the human 
conjunctival PK properties of 3 FQs that have been approved 
for the treatment of bacterial conjunctivitis in the US within 
the past decade. Because FQs are concentration-dependent 
antibiotics, their microbial eradication rates depend upon the 
concentration that they achieve at the site of infection. The 
conjunctival biopsy model provides a standardized method 
for assessing drug tissue concentrations that are relevant to 
bacterial conjunctivitis. The model is particularly useful for 
analyzing drug concentrations at multiple time intervals after 
drug instillation.
Several conjunctival tissue penetration studies have previ-
ously been conducted in humans.15,16,18 Aihara et al compared 
levofloxacin, gatifloxacin, and moxifloxacin levels in diseased 
pterygium tissue collected at 10, 30, and 45 minutes after a 
single dose. They found that the concentration of moxifloxa-
cin was higher than the other FQs at all sample times, with a 
Cmax of 116.7 ± 28.9 µg/g at 10 minutes after instillation. At 30 
minutes, the mean concentrations of levofloxacin, gatifloxa-
cin, and moxifloxacin were 11.3 ± 2.3 µg/g, 11.8 ± 3.9 µg/g, 
and 19.0 ± 6.3 µg/g, respectively. All of these values are 
markedly higher than the mean concentrations observed in 
the present study. However, in the Aihara study, BAK-free for-
mulations of levofloxacin and gatifloxacin were used, which 
are not available in the US. It is unknown how this difference, 
as well as the collection of diseased pterygium, as opposed 
to healthy conjunctiva tissue, affected their results. Wagner 
et al detected a trend similar to the one found by Aihara et al 
yielding comparable levofloxacin and gatifloxacin concen-
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Figure 3 Mean fluoroquinolone concentration-time curves in conjunctiva (mITT population).
Notes: Concentration data for biopsies performed at 24 hours are presented as a separate figure (Figure 3).
Abbreviation: mITT, modified intent-to-treat population (N = 108).
Table 5 Area-under-the-curve over 24 hours (AUC0–24 h) and mean 
residence time (MRT) for fluoroquinolones in conjunctiva
Fluoroquinolone AUC0–24 h (µg•h/g) MRT (h)a
Besifloxacin 6.65 4.7
Moxifloxacin 11.1 3.0
Gatifloxacin 6.10 2.9
aMean residence time (MRT) corresponds to 1.44 multiplied by the half-life (in 
hours) of the drug. MRT was calculated using the equation: MRT = AUMC/AUC 
(AUMC = area-under-the-first-moment-curve;   AUC = area-under-the-curve).Clinical Ophthalmology 2010:4 338
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trations (2.34 µg/g and 2.54 µg/g, respectively) in healthy 
conjunctiva collected at 20 minutes after a single dose. The 
concentration of moxifloxacin (18.0 µg/g) was relatively 
greater. Conjunctival samples collected after a single admin-
istration in the Torkildsen et al study yielded a mean moxi-
floxacin concentration of 1.92 ± 2.03 µg/g at 30 minutes, a 
value that is nearly an order of magnitude smaller than what 
was detected in the other two studies. The results from the 
present study (eg, mean concentration of moxifloxacin at 
30 minutes: 4.04 ± 4.16 µg/g) lie somewhere between the 
concentrations detected by Torkildsen et al and those detected 
in the other two studies.
In this study, all three FQs tested had similar PK profiles; 
their concentrations peaked early and declined to a low 
level by the time 24 hours had elapsed. The Cmax achieved 
by moxifloxacin (10.7 µg/g) was approximately 2- to 5-fold 
higher than the Cmax of besifloxacin (2.30 µg/g) and of gati-
floxacin (4.03 µg/g). Moxifloxacin has a pyrrolo-pyridine 
base that makes it more lipophilic relative to other FQs; this 
difference has been proposed as the principal reason for 
moxifloxacin’s preferential absorption into ocular tissue.19 
Although the Cmax for moxifloxacin was higher, the AUC0–24 
for moxifloxacin was less than double the AUC0–24 for the 
two other FQs (Table 5). Moxifloxacin reached a relatively 
high concentration at 15 minutes (mean: 10.7 ± 5.89 µg/g), 
but its presence in the tissue declined 62.1% by 30 minutes 
(4.04 ± 4.16 µg/g). In contrast, the declines in mean 
gatifloxacin and besifloxacin concentrations from 15 to 30 
minutes were 31.5% and 0.1%, respectively. When median 
concentrations are evaluated, besifloxacin was the only 
FQ tested whose concentration increased from 15 minutes 
(1.65 µg/g) to 30 minutes (1.75 µg/g).
Large variations occurred between concentration values 
within the same cohort. Most standard deviations (SDs) 
in mean concentration ranged from 50% to 100% of the 
mean value. A similar trend was detected in the Torkildsen 
et al study in 2008. Individual variations in conjunctival 
tissue and/or tear flow may be responsible. The sample size 
for this study (n = 108) was large, but treatment cohort sizes 
were small (n = 6). Cohort sizes could be increased in future 
studies to investigate reasons behind the differential absorp-
tion of drug between individuals.
Besifloxacin demonstrated the most stable behavior in 
conjunctival tissue, having the greatest MRT of 4.7 hours. 
This finding may be attributable to differences in the vehicles 
between besifloxacin and the other two FQs. The besifloxacin 
formulation used in the present study contains DuraSite® 
(InSite Vision, Inc., Alameda, California, USA), a proprietary 
polymeric mucoadhesive delivery system that has been shown 
to enhance drug residence time on the ocular surface.20
The ratio of antibiotic concentration to MIC is another 
important contributor to fluoroquinolones’ microbiologic 
efficacy. For fluoroquinolones, the AUC0–24 h:MIC90 ratio is 
the pharmacodynamic parameter that best correlates with 
clinical efficacy.11–14 Furthermore, the greater the AUC0–24 h:
MIC90 ratio, the less likely antibiotic resistance is to emerge 
among bacteria.21 Many non-ocular studies have established 
AUC0–24 h:MIC90 breakpoints that describe the level of dosing 
needed to promote clinical success. For example, a human 
study on respiratory tract infections caused by S. pneumoniae 
found that treatment with gatifloxacin at an AUC0–24 h:MIC90 
ratio 33.7 predicted clinical resolution of infection.12 There 
are limited studies of the significance of AUC:MIC ratios in 
ocular infection. In 2003, Wilhelmus performed a study of 
bacterial keratitis patients (N = 391) receiving ciprofloxacin 
drops. Using an estimated AUC0–24 h value of 68.5 µg/mL 
and an MIC90 value specific to each patient’s bacterial 
isolate, Wilhelmus plotted patient values for AUC0–24 h:
MIC90 against clinical resolution. The breakpoint for 90% 
predicted clinical improvement was an AUC0–24 h:MIC90 ratio 
of 151.22 However, the study did not account for individual 
variation in the concentration-time curve, which our study 
Table 6 Treatment-related adverse events (AEs) occurring in the safety population
Besifloxacin  
0.6% N = 37
Moxifloxacin  
0.5% N = 36
Gatifloxacin  
0.3% N = 36
Total 
N = 109
Ocular pain 3 (8.1%) 1 (2.8%) 1 (2.8%) 5 (4.6%)
Foreign body sensation 0 (0.0%) 0 (0.0%) 1 (2.8%) 1 (0.9%)
Blurred vision 1 (2.7%) 0 (0.0%) 0 (0.0%) 1 (0.9%)
Dysgeusia 0 (0.0%) 1 (2.8%) 0 (0.0%) 1 (0.9%)
Headache 1 (2.7%) 1 (2.8%) 0 (0.0%) 2 (1.8%)
Procedural site reaction 0 (0.0%) 1 (2.8%) 0 (0.0%) 1 (0.9%)
Notes: Includes AEs determined by the investigator to have a possible, probable, or definite relationship to the study medication.Clinical Ophthalmology 2010:4 339
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suggests to be significant based on the large SD values for 
drug concentrations in each treatment cohort (Table 4). The 
authors are unaware of any pharmacodynamic studies that 
establish therapeutic AUC0–24 h:MIC90 breakpoints for gati-
floxacin, moxifloxacin, or besifloxacin in ocular infection.
In this PK study, the quantity of moxifloxacin 
(AUC0–24 h = 11.1 µg•h/g) delivered to the tissue over 
the course of 24 hours was almost twice the amount of 
besifloxacin (AUC0–24 h = 6.65 µg•h/g) or gatifloxacin 
(AUC0–24 h = 6.10 µg•h/g) delivered. As discussed previously, 
the potential clinical significance of this PK data is only 
relevant when one also compares the MIC90 values for these 
agents against specific pathogens. In theory, based on the 
AUC0–24 h values observed in this study, moxifloxacin would 
offer a potential therapeutic advantage in the conjunctiva 
in cases where the MIC90 value for moxifloxacin was up to 
2-fold higher than the MIC90 for besifloxacin or gatifloxacin. 
In contrast, the available PK data indicate that the potential 
therapeutic efficacy of besifloxacin or gatifloxacin would be 
better than moxifloxacin in cases where the MIC90 value for 
moxifloxacin was more than 2-fold higher than the MIC90 
for besifloxacin or gatifloxacin.
This relationship can be illustrated by using actual 
relevant MIC90 data to calculate AUC0–24 h:MIC90 ratios for 
each of the drugs. In this example, the ratios were calculated 
using MIC90 values for ocular isolates collected from very 
recent phase 3 studies of bacterial conjunctivitis in the US 
(Table 1; Figures 4–7). When AUC0–24 h:MIC90 ratios are 
calculated for the FQs against Staphylococcus organisms, 
besifloxacin has the greatest AUC0–24 h:MIC90 ratios and is the 
only FQ to achieve an AUC0–24 h:MIC90 ratio in excess of 100 
for MSSA and MSSE (Figures 4 and 6). In the case of the 
methicillin-resistant S. epidermidis, the AUC0–24 h:MIC90 ratio 
for besifloxacin was 1.7, compared with moxifloxacin and 
gatifloxacin ratios of 0.2 and 0.05, respectively (Figure 7). 
A similar trend was observed for MRSA (Figure 5). In each 
instance, besifloxacin had the highest AUC0–24 h:MIC90 ratio 
for all Staphylococcus organisms. This suggests that one dose 
of besifloxacin may be more potent than a dose of gatifloxacin 
or moxifloxacin in treating an ocular Staphylococcus 
infection. While calculation of AUC0–24 h:MIC90 ratios using 
different MIC90 datasets may yield somewhat different 
results, this example illustrates the importance of considering 
PK and PD data in parallel. Furthermore, the microbiological 
data used in this example consists of MIC90 values that were 
determined for each fluoroquinolone under identical labora-
tory conditions, using a relevant and recently collected set 
of ocular isolates.
The illustrative example of AUC0–24 h:MIC90 ratios 
  demonstrates that AUC0–24 h:MIC90 ratios were low (ie, 2) 
for resistant Staphylococcus organisms, regardless of the 
fluoroquinolone. However, a typical treatment regimen for 
bacterial conjunctivitis includes multiple doses per day, pro-
ducing an AUC0–24 h that would be greater than that observed 
in the present study following a single instillation. It is also 
important to consider the concentration of drug in the tear 
film. Gatifloxacin, moxifloxacin, and besifloxacin are present 
in tear film at concentrations that are markedly higher than 
the conjunctival concentrations measured in this study. The 
relative contribution of these high tear concentrations to the 
effective eradication of resistant bacteria has not been estab-
lished. A previous PK study for besifloxacin revealed that the 
maximum besifloxacin concentrations in tear fluid after a single 
instillation were 610 µg/g, which is approximately 265-fold 
higher than the maximum besifloxacin concentration observed 
in conjunctiva in the present study.23 At 24 hours after a single 
dose, besifloxacin concentrations in tears were approximately 
50-fold higher than the conjunctival concentrations detected 
in this study. The concentration of drug in the tear may act 
synergistically with conjunctival drug concentration to con-
tribute to the effective treatment of bacterial conjunctivitis. 
More work is needed to understand how drug concentrations 
in the tear and the conjunctiva affect the bacterial eradication 
in the human eye.
In general, all three FQs were well tolerated. Treatment-
related AEs were not serious and were infrequent.
As concerns grow about resistant ocular infections, 
  clinicians must pay special attention to an ocular antibiotic’s 
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methicillin-sensitive S. aureus (MSSA) (mITT population).a
aMIC90 values were obtained from susceptibility testing of 144 methicillin-sensitive, 
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efficacy against multidrug-resistant organisms (MDROs). 
Susceptibility surveys such as the Ocular TRUST reveal an 
increasing incidence of MDROs in ocular infections.6 The 
resistance profile of ocular Staphylococcus bacteria should be 
considered when selecting a therapeutic agent for an ocular 
infection. The results from this study suggest that besifloxacin 
may be a preferable treatment, based on its achievement of the 
greatest AUC0–24 h:MIC90 ratio for resistant and non-resistant 
strains.
This single-dose, randomized study successfully 
characterized the human conjunctival PK of besifloxacin, 
a novel chloro-fluoroquinolone. It also provides the first 
report comparing the PK of these three fluoroquinolones in 
the conjunctiva of healthy volunteers. Because these three 
medications provide broad-spectrum coverage and cause few 
adverse reactions, they offer excellent therapeutic choices for 
treating bacterial conjunctivitis.
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